$NeuroSense Therapeutics (NRSN.US)$ NEWS NeuroSense Presents...
NEWS
NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting
Positive clinical outcomes from the PARADIGM Phase 2b study of PrimeC for ALS
Statistically significant slowing of disease progression by 37% in the per-protocol population
Validation of topline data by the American Academy of Neurology
Positive trend towards impacting Neurofilament biomarker levels
Safety and tolerability of PrimeC demonstrated
Presentation by Dr. Merit Cudkowicz at the AAN Annual Meeting
Potential new approach for addressing ALS
Positive clinical outcomes from the PARADIGM Phase 2b study of PrimeC for ALS
Statistically significant slowing of disease progression by 37% in the per-protocol population
Validation of topline data by the American Academy of Neurology
Positive trend towards impacting Neurofilament biomarker levels
Safety and tolerability of PrimeC demonstrated
Presentation by Dr. Merit Cudkowicz at the AAN Annual Meeting
Potential new approach for addressing ALS
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
456Followers
66Following
2911Visitors
Follow